BR9607178A - Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit - Google Patents

Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit

Info

Publication number
BR9607178A
BR9607178A BR9607178-8A BR9607178A BR9607178A BR 9607178 A BR9607178 A BR 9607178A BR 9607178 A BR9607178 A BR 9607178A BR 9607178 A BR9607178 A BR 9607178A
Authority
BR
Brazil
Prior art keywords
melanocytes
hormone
stimulating
stimulating alpha
alpha
Prior art date
Application number
BR9607178-8A
Other languages
English (en)
Inventor
J Mark Quillan
Channa K Jayawickreme
Michael R Lerner
Original Assignee
J Mark Quillan
Michael R Lerner
Channa K Jayawickreme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Mark Quillan, Michael R Lerner, Channa K Jayawickreme filed Critical J Mark Quillan
Publication of BR9607178A publication Critical patent/BR9607178A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"ANTAGONISTA DE PEPTìDEO DE HORMÈNIO ESTIMULANDO <244>-MELANóCITOS, PROCESSOS PARA A INIBIçãO DA ATIVIDADE DE HORMÈNIO ESTIMULANDO <244>-MELANóCITOS EM UM TECIDO OU CéLULA QUE RESPONDE A HORMÈNIO ESTIMULANDO <244>-MELANóCITOS, PARA O CLAREAMENTO DA COMPLEXAçãO DE UM ANIMAL E PARA O TRATAMENTO DE MELANOMA MALIGNO, COMPOSIçãO FARMACêUTICA, E, KIT". Os antagonistas de peptídeos de hormónio estimulando <244>-melanócitos são descritos, junto com processos para inibir os efeitos de hormónio estimulando <244>-melanócitos ou células ou tecidos sensíveis a este hormónio. Em particular, processos para o branqueamento da pigmentação da pele e para o tratamento de melanoma maligno, assim como kits para praticar a invenção são descritos também.
BR9607178-8A 1995-01-17 1996-01-16 Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit BR9607178A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/373,151 US6602856B1 (en) 1995-01-17 1995-01-17 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon
PCT/US1996/000404 WO1996022760A2 (en) 1995-01-17 1996-01-16 Antagonists of alpha-melanocyte stimulating hormone and methods based thereon

Publications (1)

Publication Number Publication Date
BR9607178A true BR9607178A (pt) 2004-10-19

Family

ID=23471196

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9607178-8A BR9607178A (pt) 1995-01-17 1996-01-16 Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit

Country Status (7)

Country Link
US (1) US6602856B1 (pt)
EP (1) EP0804217A4 (pt)
JP (1) JPH10512580A (pt)
AU (1) AU722061B2 (pt)
BR (1) BR9607178A (pt)
CA (1) CA2210737A1 (pt)
WO (1) WO1996022760A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8912698A (en) 1997-08-19 1999-03-08 University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication using d-amino acid peptides
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
DE102006011883A1 (de) * 2006-03-09 2007-09-13 Beiersdorf Ag Tropolon- und Hydroxybenzol-substituierte Oligopeptide zur Depigmentierung
CA2728140C (en) * 2007-06-27 2019-09-03 The Board Of Trustees Of The Leland Stanford Junior University Peptide tyrosinase inhibitors and uses thereof
CN104083752B (zh) * 2007-06-27 2018-04-10 里兰斯坦福初级大学理事会 寡肽酪氨酸酶抑制剂及其应用
US10836791B2 (en) * 2016-09-15 2020-11-17 Dsm Ip Assets B.V. Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305872A (en) 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
IT1148005B (it) * 1981-04-09 1986-11-26 Leonida Grippa Tripeptide nelle sue sei combinazioni amminoacide alania fenilalanina e leucina in particolare fenil-alanina-alanina-leucina (p-a-l) aventela proprieta' di esaltare l'immunita' antivirale ed antitumorale
US4481139A (en) 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
IL74827A (en) 1984-05-21 1989-06-30 Salk Inst For Biological Studi Peptides active as gnrh antagonists and pharmaceutical compositions containing them
US5003011A (en) 1985-04-09 1991-03-26 The Administrators Of The Tulane Educational Fund Therapeutic decapeptides
DE3619633A1 (de) * 1986-06-11 1987-12-17 Hoechst Ag Peptide mit einfluss auf die diurese und natriurese, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3851226T2 (de) 1987-03-31 1994-12-08 Imp Cancer Res Tech Wachstumsfaktor-rezeptor.
US5081586A (en) * 1990-02-20 1992-01-14 Eaton Corporation Multiplexing of accessories in a vehicle

Also Published As

Publication number Publication date
CA2210737A1 (en) 1996-08-01
EP0804217A2 (en) 1997-11-05
WO1996022760A3 (en) 1996-09-26
MX9705433A (es) 1997-11-29
JPH10512580A (ja) 1998-12-02
WO1996022760A2 (en) 1996-08-01
US6602856B1 (en) 2003-08-05
AU722061B2 (en) 2000-07-20
EP0804217A4 (en) 1999-09-01
AU4697796A (en) 1996-08-14

Similar Documents

Publication Publication Date Title
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DK0752842T3 (da) Præparater med forbedret stabilitet til kunstig solbruning
DE69022722D1 (de) Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
DE69938871D1 (de) Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen
ATE218854T1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase
ATE277515T1 (de) Verfahren zur behandlung von pigmentierten krebszellen durch photodynamische therapie
Piercey et al. Analgesic activities of spinal cord substance P antagonists implicate substance P as a neurotransmitter of pain sensation
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
DK0837935T3 (da) Den 3&#39;-ikke-translaterede region af det humane prohibitin-gen
ATE235190T1 (de) Bestimmung der krebsanfälligkeit eines organs oder gewebes durch bestimmung seiner zellprägung
BR9607178A (pt) Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit
DE69825279D1 (de) Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
ATE359774T1 (de) Taurinderivate verwendbar in der behandlung von netzhauterkrankungen
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DE69814691D1 (de) Verwendung von fc101 als hemmstoff der angiogenese zur behandlung von krebs und anderen angiogenen krankheiten

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]